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Most RNA viruses have evolved mechanisms to avoid neutralizing antibody responses, and it is generally believed that variability of
envelope-encoding regions is the major molecular basis of this phenomenon. However, it has been hypothesized that other mechanisms can
be involved. Recent experimental data indicate that in hepatitis C virus (HCV) infection, the anti-envelope humoral response includes cross-
reactive antibody clones able to neutralize vesicular stomatitis virus (VSV) pseudotypes containing HCV E1 and E2 glycoproteins (HCV/
VSV pseudotype) as well as other clones devoid of such activity. In this work, we demonstrate that natural infection with a large variety of
HCV isolates belonging to different genotypes elicits HCV/VSV pseudotype-neutralizing cross-reactive anti-envelope antibodies together
with clones unable to neutralize this pseudovirus. This was shown by designing a novel strategy for quantitation of serum antibodies binding
selectively to single viral cross-reactive conformational epitopes. These data can be useful not only for a better understanding of the virus–
host interplay in important viral diseases, but also for the development of an effective anti-HCV vaccine.
D 2004 Elsevier Inc. All rights reserved.
Keywords: Hepatitis C virus; Persistent infection; Anti-HCV humoral response; Quantitation of antibody subpopulationsIntroduction
Hepatitis C virus (HCV) infection is a major health
problem affecting 170 million people, or 3% of the world
population (Lauer and Walker, 2001). Unfortunately, its
most striking feature is the tendency toward chronicity
(Cerny and Chisari, 1999) associated with continuous viral
replication (Alter et al., 1992), reflecting the inability of the
immune response to clear the infection completely in the
majority of patients.0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.042
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+39 071 5964850.
E-mail address: robertoburioni@yahoo.com (R. Burioni).Humoral immunity directed against HCV antigens is
readily detected, and the demonstration of specific anti-
HCV antibodies is the basis of serologic diagnosis of
infection (Alter et al., 1989); however, the role of antibodies
in protecting from viral infection or in determining disease
progression is still unclear. Studies in chimpanzee (Farci et
al., 1992), the only available HCV model, and in poly-
transfused thalassemic children (Lai et al., 1994) have
demonstrated that even in the presence of a high titer of anti-
HCVantibodies, a new challenge of convalescent hosts with
HCV results in reinfection. In contrast to these findings,
there is in vivo and in vitro evidence that HCV infection
gives rise to a neutralizing response (Bjoro et al., 1994;
Farci et al., 1994; Zibert et al., 1995) and that an important
viral target of these antibodies is the E2 envelope
glycoprotein. Finally, prophylactic administration of anti-04) 242–248
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individuals at risk has resulted in protection from sexually
transmitted infection (Piazza et al., 1997).
A contribution to the knowledge of the anti-HCV/E2
immunoresponse has come from the dissection of the
humoral response against this antigen. Cloning of the IgG1/
k immune repertoire of an HCV-infected patient in phage
display combinatorial vectors and the subsequent generation
of recombinant monoclonal Fab fragments representing
discrete parts of the human response to a real in vivo
infection (Burioni et al., 1998c, 2001b; Plaisant et al., 1997)
demonstrated that, at least when analyzed in terms of its
ability to neutralize viral pseudotypes bearing HCVenvelope
glycoproteins on their surface, the immunoresponse is highly
heterogeneous, as clones endowed with very strong activity
coexist with clones that are totally devoid of it (Burioni et al.,
2002). The utilization of these Fabs in defining human B cell
epitopes on HCV/E2 allowed to demonstrate the presence of
at least four major epitopes, only two of which are recognized
by pseudovirus-neutralizing Fabs, suggesting that these
antibody fragments interact with a region of E2 indispensable
for viral functions. A crucial issue is to understand whether
these antibodies are reacting against conserved regions of the
viral envelope. In fact, the Fabs were selected in a way that
should have privileged cross-reactive epitopes; more in
detail, they were obtained by cloning the Fab-coding genes
from a patient infected with an HCV of a genotype (1b)
different from the one of the protein used for selection (1a)
(Lesniewski et al., 1995; Ogata et al., 1991). Given the huge
E2 heterogeneity among HCVisolates of different genotypes,
it is very likely that these Fabs are directed against conservedFig. 1. Schematic representation of FIT. The upper portion of the scheme portrays
triangle) of an antigen in the absence of any competing agent. In the lower section,
In A and B, probe binding is inversely affected by the titer of epitope-specific serum
exert any influence on the amount of bound probes.regions of envelope glycoproteins. Furthermore, our experi-
ments clearly demonstrated that all these Fabs react with E2
of the 1a genotype and at the same time immunoprecipitate
pseudoviruses constructed with E2 of the 1b genotype (Bugli
et al., 2001; Burioni et al., 2002). Avery important issue for a
proper comprehension of the virus–host interplay at this stage
is to determine whether similar antibodies are elicited by
infections caused by HCV strains of different genotypes.
To study this aspect, using the epitope map generated in
previous work (Bugli et al., 2001), we devised a novel
method for the indirect serum measurement of antibodies
directed against the different epitopes of E2 recognized by
our anti-HCV/E2 human monoclonal recombinant Fabs: the
determination of the Fab Inhibition Titer (FIT). The
quantitation strategy relies on the demonstration of the
inhibition of binding of FLAG-labeled human recombinant
Fabs (FLAG-Fabs) to bound HCV/E2 antigen using an
enzyme-linked immunoassay (Fig. 1). The system was
evaluated using mock sera containing known amount of
epitope-specific IgG1 human monoclonal antibodies. The
method is shown to be simple, reproducible, easy to perform
in an ELISA format, and can help elucidate the role of the
antibodies directed against the different parts of the E2
molecule.Results and discussion
The appropriate FLAG-Fab concentration employed in
the assay was determined for each FLAG-Fab and was the
one giving approximately 50% of maximum reading,the specific binding of three probes (FLAG-Fabs) to a single epitope (black
the binding of the same FLAG-Fabs in three different conditions is depicted.
antibodies (black Igs); in C antibodies from an HCV-negative serum do not
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FLAG), and 10 Ag/ml (e137-FLAG). Mean optical densities
(ODs) taken as reference values (and relevant standard
deviations) were 1.1 (F0.15) for e8-FLAG, 1.2 (F0.10) for
e20-FLAG, and 1.0 (F0.10) for e137-FLAG. Determination
of FIT was performed on 10 HCV-negative sera; the value
obtained was consistently b1:10, the upper detection limit of
our test, indicating that no inhibition occurred in the absence
of specific anti-HCV antibodies (Fig. 2).
To demonstrate that FIT effectively measures the anti-
bodies directed against epitopes recognized by each FLAG-
Fab, the same analysis was performed on mock specimens
prepared by spiking negative sera with human monoclonal
antibodies of given specificity, obtaining mock samples
containing known amounts of IgG directed against the
HCV/E2 epitopes defined by two of our Fabs. Results (Fig.
3) showed a linear correlation between the binding of
labeled Fabs and the amount of corresponding IgG antibodyFig. 2. Competition with unlabeled Fabs and HCV-negative sera. In the upper row
with unlabeled Fabs directed against the same epitopes and with uninfluential Fab
sera is represented.present in the mock specimen, indicating that FIT can
provide reliable information on the amount of epitope-
specific antibodies in a patient’s serum.
On the assumption that FIT measures the amount of
antibodies recognizing the same epitopes recognized by
our anti-HCV/E2 human monoclonal recombinant Fabs,
we used this method to demonstrate whether such anti-
bodies are elicited in patients infected with HCV of
genotypes other than 1a and 1b. For all the epitopes
studied in our work, FIT was consistently positive in most
HCV-infected sera with a wide range of dilutions. FIT was
very diverse for the different epitopes in the same serum
sample, with considerable heterogeneity between patients.
A summary of FIT values against different Fabs and
information on patients and viral genotypes is reported in
Table 1, showing no predictable correlation between the
total anti-E2 titer and the amount of antibodies directed
against single epitopes as measured by FIT. With a view to, the FLAG-Fabs (e8; e20; e137) used as probes in this study are competed
s (AF). In the lower row, FIT determination on three different HCV-negative
Fig. 3. Competition with mock HCV-positive sera. The validation of FIT was performed on artificial HCV-positive sera with a given amount of characterized
anti-HCV/E2 antibodies. In A, the specific probe (e509-FLAG) is inhibited only by the serum containing an increasing amount of the same antibody as whole
IgG1 (e509 IgG1). No significant inhibition is evidenced, even at the highest concentration, with the serum containing an antibody (e8 IgG1) directed against a
different epitope. In B, data obtained with e8-FLAG as probe are reported.
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conformational changes induced by other antibodies, we
spiked FIT-negative sera with known amounts of recombi-
nant Ig; these mock specimens exhibited restored FIT
activity corresponding with the Ig concentration used (data
not shown).Table 1
Characteristics of the HCV-positive sera used in this study
Serum Genotype Viral load (IU/ml) Tite
HCV genotype 1
1 1a 5,724,000 1:51
2 1b 1,197,000 1:10
3 1a 57,000 1:25
4 1b 49,000 1:51
5 1b 1,343,000 1:51
6 1b 389,000 1:51
7 1b 606,000 1:25
8 1a 2,495,000 1:10
9 1b 1,038,000 1:51
10 1a 20,000 1:20
11 1b 405,000 1:12
12 1a 4,162,000 1:20
HCV genotypes other than 1
13 3a 1,000,000 1:20
14 3a 751,000 1:64
15 2a/2c 605,000 1:20
16 3a 966,000 1:25
17 3a 1,050,000 1:10
18 3a 276,000 1:51
19 4c/4d 397,000 1:10
20 3a 1,060,000 1:51
21 2a/2c 680,000 1:25
22 2a/2c ND 1:51
23 3a 1,026,530 1:10
24 2a/2c 882,219 1:25In this paper, we describe a new method for assessing the
presence in patients’ sera of antibodies able to inhibit human
recombinant Fab binding to the E2/HCV glycoprotein and
its use in demonstrating that all HCVs are able to elicit
cross-reactive and HCV/vesicular stomatitis virus (VSV)
pseudotype-neutralizing antibodies. The test is specific, asr on HCV/E2-1a FIT
e8 e20 e137
20 160 20 b10
,240 40 80 80
60 20 80 320
20 b10 80 40
20 b10 640 160
20 80 80 20
60 40 160 20
,240 320 160 b10
20 160 640 160
,480 640 640 640
80 160 80 40
,480 640 640 80
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,240 80 320 320
20 40 160 80
,240 320 1280 320
20 40 640 640
60 b10 80 20
20 40 160 20
,240 640 640 640
60 80 640 80
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negative subjects. In addition, mock specimens were used to
demonstrate that FIT is related to the amount of serum
antibodies competing with our Fabs. The possibility that
viral glycoproteins bound to an ELISAwell (or presented on
the surface of a pseudotype virion) could not have the same
conformation as the genuine HCV particle does remain;
however, all the anti-E2 human monoclonal antibodies used
in this study have been elicited by a natural infection, so—at
least from a theoretical standpoint—they should recognize
viral proteins in their native conformation. However,
because large amounts of purified clonal virus are not
available, this cannot be proved materially. This assay
provides an indirect measure of the amount of antibodies
directed against the different human B epitopes present in
the E2 molecule and recognized by our Fabs. As these
epitopes are not reproducible by synthesizing synthetic
peptides (Burioni et al., 1998c), this is at present the only
way to determine the amount of antibodies against
conserved conformational epitopes of E2. Analysis of
several sera from patients persistently infected with HCV
indicated how antibodies corresponding with the clones
previously studied and shown to have a neutralizing effect
on an HCV/VSV pseudovirus model are elicited by
interaction of the human immune system with HCVs of
different genotypes. Though little is still known about the
role that antibodies play during HCV infection, anti-E2
antibodies per se are known to afford no protection and to
have no association with a better prognosis. In effect, there
was no predictable correlation between FIT against a given
epitope and overall anti-E2 serum titer; this may explain the
lack of protection even in the presence of a strong anti-E2
antibody response. With the method described above, the
different populations of the antibodies that recognize
different parts of the E2 molecule can now be measured
and their level correlated with clinical and epidemiological
data.
The present study does not address the question whether
a particular FIT in a given serum correlates with a better
prognosis or with given clinical features, nor whether a
higher FIT corresponds with a higher pseudovirus-neutral-
izing titer of the serum, which could be the sum of the
activities of all the antibody clones elicited by the virus. The
evaluation of the biological activity of our monoclonal
antibodies, and as a consequence also of the serum
antibodies we measure, depends strongly on the availability
of novel and more efficient HCV neutralization models.
However, our method in conjunction with more accurate
neutralization assays and with the determination of viral
sequences in selected patients, for example, patients with
spontaneously resolving infection or newborns—where the
immune pressure seems to be crucial in driving viral escape
mutants emergence (Manzin et al., 2000)—can be very
useful in elucidating the virus–host interplay and in
shedding light on the emergence of viral variants escaping
the immune system.In conclusion, the FIT test described in this paper is a fast
and high-throughput assay able to measure the amount of
antibodies directed against discrete HCV/E2 epitopes. Using
this novel assay, we were able to demonstrate that cross-
reactive antibodies binding to the same epitopes recognized
by HCV/VSV pseudovirus-neutralizing human monoclonal
antibodies are present after infection due to a broad variety
of virus variants. The antibody response against the major
HCV glycoprotein, considered the most important viral
structure interacting with cellular targets in the initiation of
HCV infection, can now be dissected and studied to a deeper
level, obtaining new information on the complex interplay
between antibodies and virus.Materials and methods
Anti HCV/E2 human Fabs, FLAG-Fabs, and monoclonal
antibodies
Generation, purification, and characterization of the anti-
HCV/E2 Fabs used in this study have been described
(Burioni et al., 1998c). FLAG-Fabs (Fabs labeled with a
FLAG epitope fused at the carboxyterminal of the heavy
chain fragment with a pentapeptide bridge) were constructed
and purified as described (Burioni et al., 2001a, 2001b).
Briefly, FLAG-Fabs were produced using the pComb3/
FLAG vector, derived from pComb3/CAF, an expression
vector retaining the SpeI restriction site 3’ of the heavy
chain fragment (Burioni et al., 1998a). A synthetic DNA
fragment coding for a gly-gln-ala-gly-pro-(FLAG) peptide
(Hopp et al., 1988) was used to replace the SpeI–NheI
fragment of pComb/CAF, thus generating—with the correct
orientation—a new vector (pComb3/FLAG) expressing the
recombinant Fab fused to the FLAG epitope, which is
recognized by a mouse monoclonal antibody (anti-FLAG
M2, Sigma, Saint Louis, MO). Fabs and FLAG-Fabs used in
this study were produced by cloning the genes coding for
the desired Fab heavy and light chain fragments into
pComb3/CAF and pComb3/FLAG, respectively. The Fab
was transferred from the pComb3/CAF vector to the
pComb3/FLAG vector by cutting pComb3/CAF with
SpeI–SacI or SpeI–EcoRI (depending on the presence of
the SacI or the EcoRI site in the heavy chain fragment
sequence) and ligating the corresponding fragment in the
identically cut pComb3/CAF containing the genes coding
for the desired Fab. This procedure transformed the
pComb3/CAF vector in a pComb3/FLAG vector, producing
FLAG-Fabs. Phagemid-transformed E. coli XL-1 Blue was
used as a source for Fab production in bacterial cultures. For
this purpose, a single colony obtained from transformation
was inoculated into 10 ml SB (Barbas et al., 1991)
containing ampicillin (50 Ag/ml); after 8 h of incubation at
37 8C, isopropyl-beta-d-thio-galactopyranoside was added
to a final concentration of 1 mM and cells were incubated
for an additional 14 h at 30 8C in a rotatory shaker. Bacteria
R. Burioni et al. / Virology 327 (2004) 242–248 247were harvested by centrifugation at 5000  g for 20 min,
resuspended in 1 ml of phosphate-buffered saline (PBS)/1%
bovine serum albumin (BSA, Sigma), and lysed by a freeze–
thawing procedure (Williamson et al., 1993). Cell debris
was removed by centrifugation in a microfuge at 15,000  g
for 5 min at room temperature and supernatants were used in
ELISA experiments. When necessary, Fab and FLAG-Fab
were purified by immunoaffinity and quantified as described
(Barbas et al., 1992).
Standardization of the assay was performed using Fab-
coding genes to construct full-size human monoclonal
antibodies (HuMabs), which were inserted in an appropriate
eukaryotic vector for subsequent production in transfected
CHO-K1 cells as described (Burton et al., 1994). The
HuMabs present in the culture supernatant were purified by
immunoaffinity (Barbas et al., 1992) and purity-checked by
PAGE. The amount of human antibody was assayed by a
sandwich immunoassay (Burton et al., 1994). All antibodies
and Fabs were stored at 70 8C until use. Sera obtained
from healthy donors and HCV-positive patients were tested
using commercial kits for anti-HCV antibody (Vitros Anti-
HCV assay; Ortho, Raritan, NJ, USA), viral load (Cobas
Amplicor HCV monitor assay 2.0; Roche Molecular
Diagnostics, Tokyo, Japan), and viral genotype (INNO-
LiPA HCV II test; Innogenetics, Ghent, Belgium). For the
preparation of mock specimens with known amounts of
antibodies directed against a given epitope, HCV-negative
sera were spiked with concentrated purified human mono-
clonal antibodies in PBS. From this point on, mock
specimens were treated exactly like the positive and
negative sera.
Fab inhibition titer (FIT) assay
The purpose of the FIT assay is to assess the ability of
sera to inhibit the binding of a labeled Fab to its epitope,
thus obtaining an indirect measure of the amount of epitope-
binding serum antibodies. From the practical point of view,
as a first step FLAG-Fabs were purified and assayed in a
FLAG-Fab-specific ELISA (Burioni et al., 2001a) to
determine the correct concentration to be used in inhibition
experiments. Briefly, FLAG-Fab preparations of known
concentration were titered by ELISA (Williamson et al.,
1993) using plates coated overnight at 4 8C with recombi-
nant HCV/E2 (genotype 1a, 100 ng/well in 25 Al of coating
buffer) produced in CHO cells (Lesniewski et al., 1995).
Plates were blocked for 1 h at 37 8C with PBS/1%BSA.
After removing the blocking solution, 50 Al of progressive
dilutions of FLAG-Fab made in PBS/BSA 1% was added to
the wells and incubated for 2 h at 37 8C. Plates were washed
10 times with PBS/0.05% Tween 20 (Sigma) in an
automated plate washer (Sorin, Saluggia, Italy) before
adding 50 Al of a 10 Ag/ml solution of anti-FLAG mouse
monoclonal antibody M2 (Sigma) in PBS/BSA 1%. After 1-
h incubation at 37 8C, wells were washed 10 times with
PBS/Tween 20 as above and mouse monoclonal bindingwas revealed with horseradish peroxidase-conjugated goat
anti-mouse IgG (1:10,000 in PBS/BSA 1%; Pierce, Rock-
ford, IL). Substrate was added and plates were read for
OD450 in an automated plate reader after 30-min incubation
at room temperature in the dark. All assays were performed
at least in double. A negative control antigen (BSA) was
always included and the OD reading was subtracted as
background.
Determination of FIT in human sera
For the determination of the FIT of sera, a concentration
of purified FLAG-Fabs yielding in standard conditions an
OD450 reading equal to 50% of maximum reading was
used for further experiments of Fab inhibition ELISA. For
these experiments, plates were coated and blocked as
described above. Progressive 1:2 serum dilutions starting at
1:10 in PBS/BSA 1% were added in the amount of 50 Al
per ELISA well. After 2 h of incubation at 37 8C, purified
FLAG-Fab was added directly to serum dilutions to reach
the desired final concentration. Plates were incubated for
an additional 30 min and then processed as described
above for FLAG-Fab ELISA. A positive control sample,
containing a 20:1 excess of purified unlabeled Fab,
corresponding with 100% inhibition, was included. A
negative control sample, containing an excess of a control
uninfluential Fab (Burioni et al., 1998b) and corresponding
with 0% inhibition, was also included. The final results
were determined as percent of inhibition with the formula:
percent inhibition = 100  (OD450 of probe FLAG-Fab
alone  OD450 of probe FLAG-Fab with competing
serum)/OD450 of probe FLAG-Fab alone. The highest
serum dilution giving more than 50% inhibition of FLAG-
Fab binding was considered as the FIT for that epitope and
serum.
Moreover, anti-HCV/E2 titer was determined for each
serum. ELISA plates were coated and blocked as above and
50 Al of 1:2 progressive serum dilutions in PBS/BSA 1%
was added to the wells and incubated for 2 h at 37 8C.
Bound serum antibodies were revealed by adding 50 Al of
horseradish peroxidase-conjugated goat antihuman IgG Fc
fragment (1:6000 in PBS/BSA1%; Sigma). A negative
control antigen (BSA) was also added. As titering dilution,
the highest giving a significantly higher (differential OD450
N 0.3) signal on HCVE2 than on control antigen was
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